Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Neither saxagliptin nor alogliptin was associated with increased ? or decreased ? rates of major adverse cardiovascular events in high-risk patients with type 2 diabetes mellitus in separate randomized, double-blind, placebo-controlled trials.
The findings with respect to these recently approved antidiabetic therapies ? members of the same class of selective dipeptidyl peptidase?4 (DDP-4) inhibitors ? provide clinicians with important information to help guide treatment decision-making for patients with type 2 diabetes and cardiovascular risk, the authors concluded.
http://www.clinicalendocrinologynew...-trials/eb1c759f2fda12cc76182c0c9ec2920e.html
The findings with respect to these recently approved antidiabetic therapies ? members of the same class of selective dipeptidyl peptidase?4 (DDP-4) inhibitors ? provide clinicians with important information to help guide treatment decision-making for patients with type 2 diabetes and cardiovascular risk, the authors concluded.
http://www.clinicalendocrinologynew...-trials/eb1c759f2fda12cc76182c0c9ec2920e.html